Annexon Inc at Goldman Sachs Healthcare Conference Transcript
Good morning, everyone. Thank you for joining us on day two of the Goldman Sachs Healthcare Conference. It's my pleasure to introduce the Annexon team. With us, we have Doug Love, Chief Executive Officer and President, and Lloyd Clark, SVP, Ophthalmology Strategy. Thanks so much for being here.
To start here, perhaps a snapshot of how to think about the second-half of '26 and beyond. This is a potentially transformational year for the company with pivotal data and geographic atrophy that is expected in the fourth quarter of this year. Describe, maybe to start here, your asset, how it's differentiated from the other geographic atrophy assets, and your confidence in the Phase 3 study success.
Yeah, happy to do so, and thanks again for having us. It's delightful to be out here in Miami with. So, look, we're really excited about the Phase III asset on improvement for the treatment of geographic atrophy. I would say it's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
